HighTide Therapeutics (HKSE:02511) Cash And Cash Equivalents : HK$665.25 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Cash And Cash Equivalents?

HighTide Therapeutics's quarterly cash and cash equivalents increased from Dec. 2022 (HK$460.47 Mil) to Jun. 2023 (HK$801.65 Mil) but then stayed the same from Jun. 2023 (HK$801.65 Mil) to Dec. 2023 (HK$665.25 Mil).

HighTide Therapeutics's annual cash and cash equivalents declined from Dec. 2021 (HK$937.07 Mil) to Dec. 2022 (HK$460.47 Mil) but then increased from Dec. 2022 (HK$460.47 Mil) to Dec. 2023 (HK$665.25 Mil).

HighTide Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for HighTide Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Cash And Cash Equivalents Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

937.07

460.47

665.25

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	937.07	-	460.47	801.65	665.25

HighTide Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

HighTide Therapeutics (HKSE:02511) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

HighTide Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you
Hongtu Capital Limited	2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines